Cáncer Renal.
DOI:
https://doi.org/10.54212/27068048.v5i1.78Palabras clave:
Cáncer renal, Carcinoma de células renales, Biopsia renal, Grado de FuhrmanResumen
El diagnóstico y tratamiento del cáncer renal ha cambiado de forma importante en los últimos años. La incidencia mundial ha aumentado, pero la sobrevida también ha mejorado con el diagnóstico temprano de masas renales de forma incidental, debido al uso cada vez más frecuente de estudios de imagen del abdomen con otros fines diagnósticos.
El carcinoma de células renales es un grupo heterogéneo de tumores con subtipos histológicos y alteraciones moleculares y genéticas diversas.
Descargas
Citas
O'Connor SD, Pickhardt PJ, Kim DH, Oliva MR, Silverman SG. Incidental finding of renal masses at unenhanced CT: prevalence and analysis of features for guiding management. AJR Am J Roentgenol 2011; 197: 139-45. https://doi.org/10.2214/AJR.10.5920 DOI: https://doi.org/10.2214/AJR.10.5920
Sun M, Abdollah F, Bianchi M, et al. Treatment management of small renal masses in the 21st century: a paradigm shift. Ann Surg Oncol 2012; 19: 2380-87. https://doi.org/10.1245/s10434-012-2247-0 DOI: https://doi.org/10.1245/s10434-012-2247-0
Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal cell carcinoma. N Engl J Med 2017; 376:354-66. https://doi.org/10.1056/NEJMra1601333 DOI: https://doi.org/10.1056/NEJMra1601333
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67(1): 7-30. https://doi.org/10.3322/caac.21708
https://doi.org/10.3322/caac.21387 DOI: https://doi.org/10.3322/caac.21387
https://doi.org/10.3322/caac.21590 DOI: https://doi.org/10.3322/caac.21590
https://doi.org/10.3322/caac.21442 DOI: https://doi.org/10.3322/caac.21442
https://doi.org/10.3322/caac.21551 DOI: https://doi.org/10.3322/caac.21551
https://doi.org/10.3322/caac.21332 DOI: https://doi.org/10.3322/caac.21332
https://doi.org/10.3322/caac.21654 DOI: https://doi.org/10.3322/caac.21654
Cancer Research UK. Kidney cancer incidence statistics 2013. www.cancerresearchuk.org/cancer-info/cancerstats/types/kidney/incidence/#source17
Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol 2006; 176: 2353-8. https://doi.org/10.1016/j.juro.2006.07.130 DOI: https://doi.org/10.1016/j.juro.2006.07.130
Theis RP, Dolwick Grieb SM, Burr D, Sidiqqui T Asal NR. Smoking, environmental tobacco smoke, and risk of renal cell cancer: a population-based case-control study. BMC Cancer 2008, 8: 387. https://doi.org/10.1186/1471-2407-8-387 DOI: https://doi.org/10.1186/1471-2407-8-387
Zuchetto A, Del Masso I, Tavari A, et al. History of treated hypertension and diabetes mellitus and risk of renal cell cancer. Ann Oncol 2007; 18: 596-600. https://doi.org/10.1093/annonc/mdl438 DOI: https://doi.org/10.1093/annonc/mdl438
Zhang GM, Zhu Y, Ye DW. Metabolic syndrome and renal cell carcinoma. World J Surg Oncol 2014; 12: 236. https://doi.org/10.1186/1477-7819-12-236. https://doi.org/10.1186/1477-7819-12-204 DOI: https://doi.org/10.1186/1477-7819-12-204
Shuch B, Amin A, Armstrong AJ, et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol 2015; 67: 85-97. https://doi.org/10.1016/j.eururo.2014.04.029 DOI: https://doi.org/10.1016/j.eururo.2014.04.029
Comperat E, Varinot J. Classification of Adult Renal Tumors: An Update. Semin Ultrasound CT MRI 2017; 38: 2-9. https://doi.org/10.1053/j.sult.2016.08.004 DOI: https://doi.org/10.1053/j.sult.2016.08.004
Linehan WM, Ricketts CJ. The metabolic basis of kidney cancer. Semin Cancer Biol 2013; 23: 46-55. https://doi.org/10.1016/j.semcancer.2012.06.002 DOI: https://doi.org/10.1016/j.semcancer.2012.06.002
Sacco E, Pinto F, Sasso F. et al. Paraneoplastic syndromes in patients with urological malignancies. Urol Int 2009; 83: 1-11. https://doi.org/10.1159/000224860 DOI: https://doi.org/10.1159/000224860
Kang SK, Chandarana H. Contemporary imaging of the renal mass. Urol Clin North Am 2012; 39: 161-70. https://doi.org/10.1016/j.ucl.2012.01.002 DOI: https://doi.org/10.1016/j.ucl.2012.01.002
Griffin N, Gore ME, Sohaib SA. Imaging in metastatic renal cell carcinoma. AJR Am J Roentgenol 2007; 189: 360-70. https://doi.org/10.2214/AJR.07.2077 DOI: https://doi.org/10.2214/AJR.07.2077
Volpe A, Finelli A, Gill IS, et al. Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol 2012; 62: 491-504. https://doi.org/10.1016/j.eururo.2012.05.009 DOI: https://doi.org/10.1016/j.eururo.2012.05.009
Ball MW, Bezerra SM, Gorin MA, et al. Grade heterogeneity in small renal masses: potential implications of renal mass biopsy. J Urol 2015; 193: 36-40. https://doi.org/10.1016/j.juro.2014.06.067 DOI: https://doi.org/10.1016/j.juro.2014.06.067
AJCC TNM 8th Ed. 2016. TNM Staging System for Kidney Cancer. American Joint Committee on Cancer (AJCC).
Rendon RA. Active surveillance as the preferred management option for small renal masses. Can Urol Assoc J 2010; 4: 136-38. https://doi.org/10.5489/cuaj.812
https://doi.org/10.5489/cuaj.10038 DOI: https://doi.org/10.5489/cuaj.10038
Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 2010; 28: 111-17. https://doi.org/10.1200/JCO.2009.22.4816 DOI: https://doi.org/10.1200/JCO.2009.22.4816
Thompson TH, Atwell T, Schmit G, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015; 67: 252-59. https://doi.org/10.1016/j.eururo.2014.07.021 DOI: https://doi.org/10.1016/j.eururo.2014.07.021
Kutikov A, Smaldone MC, Uzzo RG. Focal therapy for treatment of the small renal mass: dealer's choice or a therapeutic gamble? Eur Urol 2015; 67: 260-61. https://doi.org/10.1016/j.eururo.2014.08.034 DOI: https://doi.org/10.1016/j.eururo.2014.08.034
Kunkle DA, Egleston BI, Uzzo RG. Excise, ablate or observe the small renal mass dilemma-a meta-analysis and review. J Urol 2008; 179: 1227-33. https://doi.org/10.1016/j.juro.2007.11.047 DOI: https://doi.org/10.1016/j.juro.2007.11.047
AUA Guideline. Renal Mass and Localized Renal Cancer. 2017 www.auanet.org/guidelines/renal-mass-and-localized-renal-cancer-new-(2017).
EAU Guideline. Renal Cell Carcinoma. 2018 www.uroweb.org/guideline/renal-cell-carcinoma/
Crepel M, Jeldres C, Sun M, et al. A population-based comparison of cancer control rates between radical and partial nephrectomy for T1A renal cell carcinoma. Urology 2010; 76: 883-88. https://doi.org/10.1016/j.urology.2009.08.028 DOI: https://doi.org/10.1016/j.urology.2009.08.028
Crepel M, Jeldres C, Perrote P, et al. Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment. Urology 2010; 75: 271-75. https://doi.org/10.1016/j.urology.2009.04.098 DOI: https://doi.org/10.1016/j.urology.2009.04.098
Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H. Renal function after nephron sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol 2014; 65: 372-77. https://doi.org/10.1016/j.eururo.2013.06.044 DOI: https://doi.org/10.1016/j.eururo.2013.06.044
Capitanio U, Terrone C, Antonelli A, et al. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. Eur Urol 2015; 67: 683-89. https://doi.org/10.1016/j.eururo.2014.09.027 DOI: https://doi.org/10.1016/j.eururo.2014.09.027
Terrone C, Volpe A. Can emerging level 1 evidence "discourage" elective nephron-sparing surgery for small renal tumors? Eur Urol 2011; 59:553-55. https://doi.org/10.1016/j.eururo.2010.12.041 DOI: https://doi.org/10.1016/j.eururo.2010.12.041
Volpe A, Blute ML, Ficarra V. et al. Renal ischemia and function after partial nephrectomy: a collaborative review of the literature. Eur Urol 2015; 68: 61-74. https://doi.org/10.1016/j.eururo.2015.01.025 DOI: https://doi.org/10.1016/j.eururo.2015.01.025
Thompson RH, Kaag M, Vickers A, et al. Contemporary use of partial nephrectomy at a tertiary care center in the United States. J Urol 2009; 181: 993-97. https://doi.org/10.1016/j.juro.2008.11.017 DOI: https://doi.org/10.1016/j.juro.2008.11.017
Hemal AK, Kumar A, Kumar R, et al. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. J Urol 2007; 177: 862-66. https://doi.org/10.1016/j.juro.2006.10.053 DOI: https://doi.org/10.1016/j.juro.2006.10.053
Asimakopoulos AD, Miano R, Annino F, et al. Robotic radical nephrectomy for renal cell carcinoma: a systematic review. BMC Urol 2014; 14: 75. https://doi.org/10.1186/1471-2490-14-75 DOI: https://doi.org/10.1186/1471-2490-14-75
Bekema HJ, MacLennan S, Imamaura M, et al. Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. Eur Urol 2013; 64: 799-810. https://doi.org/10.1016/j.eururo.2013.04.033 DOI: https://doi.org/10.1016/j.eururo.2013.04.033
Capitanio UB, Becker F, Blute F, et al. Lymph node dissection in renal cell carcinoma. Eur Urol 2011; 60: 1212-20. https://doi.org/10.1016/j.eururo.2011.09.003 DOI: https://doi.org/10.1016/j.eururo.2011.09.003
Haferkamp A, Bastian PJ, Jakobi H, et al. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long term follow up. J Urol 2007; 177:1703-08. https://doi.org/10.1016/j.juro.2007.01.039 DOI: https://doi.org/10.1016/j.juro.2007.01.039
Mihaly Z, Sztupinski Z, Surowiak P, Gyorffy B. A comprehensive overview of targeted therapy in metastatic renal cell carcinoma. Curr Cancer Drug Targets 2012; 12: 857-72. https://doi.org/10.2174/156800912802429265 DOI: https://doi.org/10.2174/156800912802429265
Mickisch GH, Garin A, Van Poppel H, de Prijck I, Sylvester R. Radical nephrectomy plus interferon-alfa based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 2001; 358: 966-70. https://doi.org/10.1016/S0140-6736(01)06103-7 DOI: https://doi.org/10.1016/S0140-6736(01)06103-7
Pindoria N, Raison N, Blecher G, Catterwell R, Dasgupta P. Cytoreductive nephrectomy in the era of targeted therapies: a review. BJU Int 2017; 120: 320-28. https://doi.org/10.1111/bju.13860 DOI: https://doi.org/10.1111/bju.13860
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2018 Juan Pablo Lezana Vega
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores/as que publiquen en esta revista aceptan las siguientes condiciones:
- Los autores/as conservan los derechos de autor y ceden a la revista el derecho de la primera publicación, con el trabajo registrado con la licencia de atribución de Creative Commons 4.0, que permite a terceros utilizar lo publicado siempre que mencionen la autoría del trabajo y a la primera publicación en esta revista.
- Los autores/as pueden realizar otros acuerdos contractuales independientes y adicionales para la distribución no exclusiva de la versión del artículo publicado en esta revista (p. ej., incluirlo en un repositorio institucional o publicarlo en un libro) siempre que indiquen claramente que el trabajo se publicó por primera vez en esta revista.
- Se permite y recomienda a los autores/as a compartir su trabajo en línea (por ejemplo: en repositorios institucionales o páginas web personales) antes y durante el proceso de envío del manuscrito, ya que puede conducir a intercambios productivos, a una mayor y más rápida citación del trabajo publicado.
